Behcets Syndrome

Drugs

Volumn 72, Issue 17, 2012, Pages 2223-2241

  Dalvi, Sam R ^a   Yildirim, Resit ^b   Yazici, Yusuf ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

Alemtuzumab; Azathioprine; Behcets syndrome; Ciclosporin; Colchicine; Corticosteroids; Cyclopentolate; Cyclophosphamide; Etanercept; Glucocorticoids; Infliximab; Methylprednisolone sodium succinate; Prednisone; Rituximab; Sucralfate; Triamcinolone; Tumour necrosis factor Alpha; Vasculitis.

Indexed keywords

ALKYLATING AGENT; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIMETABOLITE; AZATHIOPRINE; C REACTIVE PROTEIN; CALCIUM; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; GAMMA INTERFERON; HEAT SHOCK PROTEIN 65; HLA B51 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; INTERLEUKIN 6; LIVE VACCINE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MONOCLONAL ANTIBODY; PLACEBO; PREDNISONE; STEROID; TRANSCRIPTION FACTOR POU4F2; VASCULOTROPIN; VITAMIN D; ANTICOAGULANT AGENT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

ALOPECIA; AORTA STENOSIS; ARTHRALGIA; ARTHRITIS; BEHAVIOR CHANGE; BEHCET DISEASE; BONE MARROW SUPPRESSION; BONE NECROSIS; CATARACT; CONGESTIVE HEART FAILURE; COUGHING; DEMYELINATING DISEASE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ENDOCARDITIS; ERYTHROCYTE SEDIMENTATION RATE; ESCHERICHIA COLI; FAMILIAL MEDITERRANEAN FEVER; FEMALE STERILITY; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GENETIC RISK; GENITAL ULCER; GINGIVA HYPERPLASIA; GLUCOSE INTOLERANCE; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART MUSCLE FIBROSIS; HEMIPARESIS; HEMOPTYSIS; HIRSUTISM; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERURICEMIA; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION; INJECTION SITE INFECTION; INJECTION SITE REACTION; INTERSTITIAL NEPHRITIS; INTRACARDIAC THROMBOSIS; INTRACRANIAL HYPERTENSION; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MALE STERILITY; MORBIDITY; MORTALITY; MOUTH ULCER; MYOCARDITIS; MYOPATHY; NAUSEA; NONHUMAN; OSTEOPOROSIS; PANCREATITIS; PANCYTOPENIA; PATHOGENESIS; PERCEPTION DEAFNESS; PERICARDITIS; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREVALENCE; PROGNOSIS; PSORIATIC ARTHRITIS; PULMONARY ARTERY ANEURYSM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SKIN DEFECT; STREPTOCOCCUS; TH1 CELL; TH2 CELL; THORAX PAIN; THROMBOCYTOPENIA; UVEITIS; VACCINATION; VASCULITIS; VEIN THROMBOSIS; VISUAL IMPAIRMENT; DRUG ANTAGONISM; PATHOPHYSIOLOGY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE;

BACTERIA (MICROORGANISMS); PROTEA;

ANTICOAGULANTS; BEHCET SYNDROME; COLCHICINE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870006270     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11641370-000000000-00000     Document Type: Review

References (122)

1. Zouboulis CC, Keitel W. A historical review of early descriptions of Adamantiades-Behcet's disease. J Invest Dermatol 2002 Jul; 119 (1): 201-5
2. Yazici Y, Yurdakul S, Yazici H. Behcet's syndrome. Curr Rheumatol Rep 2010 Dec; 12 (6): 429-35
3. Verity DH, Marr JE, Ohno S, et al. Behcet's disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 1999 Sep; 54 (3): 213-20
4. Azizlerli G, Kose AA, Sarica R, et al. Prevalence of Behcet's disease in Istanbul, Turkey. Int JDermatol 2003 Oct; 42 (10): 803-6
5. Cakir N, Dervis E, Benian O, et al. Prevalence of Behcet's disease in rural western Turkey: a preliminary report. Clin Exp Rheumatol 2004 Jul-Aug; 22 (4 Suppl. 34): 53-5
6. Idil A, Gurler A, Boyvat A, et al. The prevalence of Behcet's disease above the age of 10 years: the results of a pilot study conducted at the Park Primary Health Care Center in Ankara, Turkey. Ophthalmic Epidemiol 2002 Dec; 9 (5): 325-31
7. Yurdakul S, Gunaydin I, Tuzun Y, et al. The prevalence of Behcet's syndrome in a rural area in northern Turkey. J Rheumatol 1988; 15 (5): 820-2
8. Kone-Paut I, Darce-Bello M, Shahram F, et al., PED-BD International Expert Committee. Registries in rheumatological and musculoskeletal conditions. Paediatric Behcet's disease: an international cohort study of 110 patients. One-year follow-up data. Rheumatology (Oxford) 2011 Jan; 50 (1): 184-8
9. Krause I, Yankevich A, Fraser A, et al. Prevalence and clinical aspects of Behcet's disease in the north of Israel. Clin Rheumatol 2007 Apr; 26 (4): 555-60
10. Papoutsis NG, Abdel-Naser MB, Altenburg A, et al. Prevalence of Adamantiades-Behcet's disease in Germany and the municipality of Berlin: results of a nationwide survey [published erratum appears in Clin Exp Rheumatol 2007 May-Jun; 25 (3): 507-8]. Clin Exp Rheumatol 2006 Sep-Oct; 24 (5 Suppl. 42): S125
11. Mahr A, Belarbi L, Wechsler B, et al. Population-based prevalence study of Behcet's disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum 2008 Dec; 58 (12): 3951-9
12. Nakae K, Masaki F, Hashimoto T, et al. Recent epidemiological features of Behcet's disease in Japan. In: Wechsler B, Godeau P, editors. Behcet's disease. Amsterdam: Excerpta Medica, 1993: 145-51
13. Yamamoto S, Toyokawa H, Matsubara J, et al. A nationwide survey of Behcet's disease in Japan. Jpn J Ophthalmol 1974; 18: 282-90
14. Mok CC, Cheung TC, Ho CT, et al. Behcet's disease in southern Chinese patients. J Rheumatol 2002 Aug; 29 (8): 1689-93
15. Ohno S, Aoki K, Sugiura S, et al. HL-A5 and Behcet's disease [letter]. Lancet 1973 Dec 15; 2 (7843): 1383-4
16. Ohno S, Asanuma T, Sugiura S, et al. HLA-Bw51 and Behcet's disease. JAMA 1978 Aug 11; 240 (6): 529
17. Moore SB, O'Duffy JD. Lack of association between Behcet's disease and major histocompatibility complex class II antigens in an ethnically diverse North American Caucasoid patient group. J Rheumatol 1986 Aug; 13 (4): 771-3
18. Gul A. Behcet's disease: an update on the pathogenesis. Clin Exp Rheumatol 2001 Sep-Oct; 19 (5 Suppl. 24): 6-12
19. Hirohata S, Oka H, Mizushima Y. Streptococcal-related antigens stimulate production of IL-6 and interferongamma by T cells from patients with Behcet's disease. Cell Immunol 1992 Apr; 140 (2): 410-9
20. Kaneko F, Oyama N, Yanagihori H, et al. The role of streptococcal hypersensitivity in the pathogenesis of Behcet's disease. Eur J Dermatol 2008 Sep-Oct; 18 (5): 489-98
21. Dalghous AM, Freysdottir J, Fortune F. Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Behcet's disease (BD) and recurrent aphthous stomatitis is Th1-Associated, although Th2-Association is also observed in patients with BD. Scand J Rheumatol 2006 Nov-Dec; 35 (6): 472-5
22. Frassanito MA, Dammacco R, Cafforio P, et al. Th1 polarization of the immune response in Behcet's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 1999 Sep; 42 (9): 1967-74
23. Raziuddin S, al-Dalaan A, Bahabri S, et al. Divergent cytokine production profile in Behcet's disease: altered Th1/Th2 cell cytokine pattern. J Rheumatol 1998 Feb; 25 (2): 329-33
24. Sakane T, Takeno M, Suzuki N, et al. Behcet's disease. N Eng J Med 1999 Oct 21; 341 (17): 1284-91
25. Sahin S, Akoglu T, Direskeneli H, et al. Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behcet's disease. Ann Rheum Dis 1996 Feb; 55 (2): 128-33
26. Musabak U, Pay S, Erdem H, et al. Serum interleukin-18 levels in patients with Behcet's disease: is its expression associated with disease activity or clinical presentations? Rheumatol Int 2006 Apr; 26 (6): 545-50
27. Pay S, Musabak U, Simsek I, et al. Expression of CXCR-1 and CXCR-2 chemokine receptors on synovial neutrophils in inflammatory arthritides: does persistent or increasing expression of CXCR-2 contribute to the chronic inflammation or erosive changes? Joint Bone Spine 2006 Dec; 73 (6): 691-6
28. Atagunduz P, Ergun T, Direskeneli H. MEFV mutations are increased in Behcet's disease (BD) and are associated with vascular involvement. Clin Exp Rheumatol 2003 Jul-Aug; 21 (4 Suppl. 30): S35-7
29. Alpsoy E, Zouboulis CC, Ehrlich GE. Mucocutaneous lesions of Behcet's disease. Yonsei Med J 2007 Aug 31; 48 (4): 573-85
30. Ergun T, Gurbuz O, Dogusoy G, et al. Histopathologic features of the spontaneous pustular lesions of Behcet's syndrome. Int J Dermatol 1998 Mar; 37 (3): 194-6
31. Alpsoy E, Donmez L, Onder M, et al. Clinical features and natural course of Behçet's disease in 661 cases: a multicentre study. Br J Dermatol 2007 Nov; 157 (5): 901-6
32. Yazici Y, Moses N. Clinical manifestations and ethnic background of patients with Behcet's Syndrome in a US cohort [abstract]. Arthritis Rheum 2007; 56: S: 502
33. Yazici H, Chamberlain MA, Tuzun Y, et al. A comparative study of the pathergy reaction among Turkish and British patients with Behcet's disease. Ann Rheum Dis 1984 Feb; 43 (1): 74-5
34. Davatchi F, Chams-Davatchi C, Ghodsi Z, et al. Diagnostic value of pathergy test in Behcet's disease according to the change of incidence over the time. Clin Rheumatol 2011 Sep; 30 (9): 1151-5
35. Davatchi F, Sadeghi Abdollahi B, Chams-Davatchi C, et al. Impact of the positive pathergy test on the performance of classification/diagnosis criteria for Behcet's disease. Mod Rheumatol. Epub 2012 Apr 4
36. Fresko I, Yazici H, Bayramiçli M, et al. Effect of surgical cleaning of the skin on the pathergy phenomenon in Behçet's syndrome. Ann Rheum Dis 1993 Aug; 52 (8): 619-20
37. Dilsen N, Konice M, Aral O, et al. Comparative study of the skin pathergy test with blunt and sharp needles in Behcet's disease: confirmed specificity but decreased sensitivity with sharp needles. Ann Rheum Dis 1993 Nov; 52 (11): 823-5
38. Hatemi G, Yazici H. Behçet's syndrome and microorganisms. Best Pract Res Clin Rheumatol 2011 Jun; 25 (3): 389-406
39. Tugal-Tutkun I, Opal S, Altan-Yaylacioglu R, et al. Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol 2004 Sep; 138 (3): 373-80
40. Maghraoui AE, Tabache F, Bezza A, et al. A controlled study of sacroiliitis in Behcet's disease. Clin Rheumatol 2001; 20 (3): 189-91
41. Yurdakul S, Yazici H, Tuzun Y, et al. The arthritis of Behcet's disease: a prospective study. Ann Rheum Dis 1983 Oct; 42 (5): 505-15
42. Diri E, Mat C, Hamuryudan V, et al. Papulopustular skin lesions are seen more frequently in patients with Behcet's syndrome who have arthritis: a controlled and masked study. Ann Rheum Dis 2001 Nov; 60 (11): 1074-6
43. Hatemi G, Fresko I, Tascilar K, et al. Increased enthesopathy among Behcet's syndrome patients with acne and arthritis: an ultrasonography study. Arthritis Rheum 2008 May; 58 (5): 1539-45
44. Karaca M, Hatemi G, Sut N, et al. The papulopustular lesion/arthritis cluster of Behcet's syndrome also clusters in families. Rheumatology (Oxford) 2012 Jun; 51 (6): 1053-60
45. TohmeA,AounN, El-RassiB, et al. Vascularmanifestations of Behcet's disease: eighteen cases among 140 patients. Joint Bone Spine 2003 Sep; 70 (5): 384-9
46. Saadoun D, Asli B, Wechsler B, et al. Long-term outcome of arterial lesions in Behcet disease: a series of 101 patients. Medicine (Baltimore) 2012 Jan; 91 (1): 18-24
47. Seyahi E, Melikoglu M, Akman C, et al. Pulmonary artery involvement and associated lung disease in Behcet disease: a series of 47 patients. Medicine (Baltimore) 2012 Jan; 91 (1): 35-48
48. Geri G, Wechsler B, Thi Huong du L, et al. Spectrum of cardiac lesions in Behcet disease: a series of 52 patients and review of the literature. Medicine (Baltimore) 2012 Jan; 91 (1): 25-34
49. Gokcay F, Celebisoy N, Gokcay A, et al. Neurological symptoms and signs in Behcet disease: a Western Turkey experience. Neurologist 2011 May; 17 (3): 147-50
50. Akman-Demir G, Serdaroglu P, Tasci B. Clinical patterns of neurological involvement in Behcet's disease: evaluation of 200 patients. The Neuro-Behcet Study Group. Brain 1999 Nov; 122 (Pt 11): 2171-82
51. Aykutlu E, Baykan B, Akman-Demir G, et al. Headache in Behcet's disease. Cephalalgia 2006 Feb; 26 (2): 180-6
52. Kulahli I, Balci K, Koseoglu E, et al. Audio-vestibular disturbances in Behcet's patients: report of 62 cases. Hear Res 2005 May; 203 (1-2): 28-31
53. Jankowski J, Crombie I, Jankowski R. Behcet's syndrome in Scotland. Postgrad Med J 1992 Jul; 68 (801): 566-70
54. Shimizu T, Ehrlich GE, Inaba G, et al. Behcet disease (Behcet syndrome). Semin Arthritis Rheum 1979 May; 8 (4): 223-60
55. Tursen U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behcet's disease. Int J Dermatol 2003 May; 42 (5): 346-51
56. Lee CR, Kim WH, Cho YS, et al. Colonoscopic findings in intestinal Behcet's disease. Inflamm Bowel Dis 2001 Aug; 7 (3): 243-9
57. Wang WB, Zhao YP, Cong L, et al. Clinical characters of gastrointestinal lesions in intestinal Behcet's disease. Chin Med Sci J 2011 Sep; 26 (3): 168-71
58. Koklu S, Yuksel O, Onur I, et al. Ileocolonic involvement in Behcet's disease: endoscopic and histological evaluation. Digestion 2010; 81 (4): 214-7
59. Akpolat T, Dilek M, Aksu K, et al. Renal Behcet's disease: an update. Semin Arthritis Rheum 2008 Dec; 38 (3): 241-8
60. International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 1990 May 5; 335 (8697): 1078-80
61. Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behcet's syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003 Jan; 82 (1): 60-76
62. Saadoun D, Wechsler B, Desseaux K, et al. Mortality in Behçet's disease. Arthritis Rheum 2010 Sep; 62 (9): 2806-12
63. Hamuryudan V, Yurdakul S, Moral F, et al. Pulmonary arterial aneurysms in Behcet's syndrome: a report of 24 cases. Br J Rheumatol 1994 Jan; 33 (1): 48-51
64. Bayraktar Y, Balkanci F, Bayraktar M, et al. Budd-Chiari syndrome: a common complication of Behcet's disease. Am J Gastroenterol 1997 May; 92 (5): 858-62
65. Hamuryudan V, Er T, Seyahi E, et al. Pulmonary artery aneurysms in Behcet syndrome. Am J Med 2004 Dec 1; 117 (11): 867-70
66. Siva A, Kantarci OH, Saip S, et al. Behcet's disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 2001 Feb; 248 (2): 95-103
67. Seyahi E, Yazici H. Prognosis in Behcet's Syndrome. In: Yazici Y, Yazici H, editors. Behcet's syndrome. New York: Springer, 2010: 285-95
68. Chung YM, Lin YC, Tsai CC, et al. Behcet's disease with uveitis in Taiwan. JChinMed Assoc 2008 Oct; 71 (10): 509-16
69. Cho YJ, Kim WK, Lee JH, et al. Visual prognosis and risk factors for Korean patients with Behcet uveitis. Ophthalmologica 2008; 222 (5): 344-50
70. Melikoglu M, Ugurlu S, Tascilar K, et al. Large vessel involvement in Behcet's syndrome: a retrospective survey [abstract]. Ann Rheum Dis 2008; 67 Suppl. II: 67
71. Diri E, Espinoza LR. Neuro-Behcet's syndrome: differential diagnosis and management. Curr Rheumatol Rep 2006 Aug; 8 (4): 317-22
72. Mat C, Yurdakul S, Uysal S, et al. A double-blind trial of depot corticosteroids in Behcet's syndrome. Rheumatology (Oxford) 2006 Mar; 45 (3): 348-52
73. Aktulga E, Altac M, Muftuoglu A, et al. A double-blind study of colchicine in Behcet's disease. Haematologica 1980 Jun; 65 (3): 399-402
74. Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 2001 Nov; 44 (11): 2686-92
75. Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behcet's disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol 2009; 19 (5): 542-9
76. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's syndrome. N Eng J Med 1990 Feb 1; 322 (5): 281-5
77. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum 1997 Apr; 40 (4): 769-74
78. Ho S, Clipstone N, Timmermann L, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996 Sep; 80 (3 Pt 2): S: 40-5
79. Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial. Br J Ophthalmol 1992 Apr; 76 (4): 241-3
80. Masuda K, Nakajima A, Urayama A, et al. Doublemasked trial of cyclosporin versus colchicine and longterm open study of cyclosporin in Behçet's disease. Lancet 1989 May 20; 1 (8647): 1093-6
81. Robertson M, Liversidge J, Forrester JV, et al. Neutralizing tumor necrosis factor-Alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2003 Jul; 44 (7): 3034-41
82. Greiner K, Murphy CC, Willermain F, et al. Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci 2004 Jan; 45 (1): 170-6
83. Chi W, Zhu X, Yang P, et al. Upregulated IL-23 and IL-17 in Behcet patients with active uveitis. Invest Ophthalmol Vis Sci 2008 Jul; 49 (7): 3058-64
84. Sugita S, Kawazoe Y, Imai A, et al. Inhibition of Th17 differentiation by anti-TNF-Alpha therapy in uveitis patients with Behcet's disease. Arthritis Res Ther 2012 May 1; 14 (3): R99
85. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med 2004 Mar 2; 140 (5): 404-6
86. Cantini F, Niccoli L, Nannini C, et al. Efficacy of infliximab in refractory Behcet's disease-Associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. Biologics 2012; 6 (5): 5-12
87. Iwata S, Saito K, Yamaoka K, et al. Efficacy of combination therapy of anti-TNF-A antibody infliximab and methotrexate in refractory entero-Behçet's disease. Mod Rheumatol 2011 Apr; 21 (2): 184-91
88. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J Rheumatol 2005 Jan; 32 (1): 98-105
89. Kotter I, Gunaydin I, Zierhut M, et al. The use of interferon alpha in Behcet's disease: review of the literature. Semin Arthritis Rheum 2004 Apr; 33 (5): 320-35
90. Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003 Apr; 87 (4): 423-31
91. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebocontrolled and double-blind study. Arch Dermatol 2002 Apr; 138 (4): 467-71
92. Hatemi G, Silman A, Bang D, et al., (EULAR Expert Committee). EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008 Dec; 67 (12): 1656-62
93. Ait Ben Haddou EH, Imounan F, Regragui W, et al. Neurological manifestations of Behçet's disease: evaluation of 40 patients treated by cyclophosphamide. Rev Neurol (Paris) 2012 Apr; 168 (4): 344-9
94. University of Leeds. Psychometric laboratory for health sciences [online]. Available from URL: http://www.leeds. ac.uk/medicine/rehabmed/ psychometric/Scales1.htm [Accessed 2012 Nov 13]
95. Lawton G, Bhakta BB, Chamberlain MA, et al. The Behcet's disease activity index. Rheumatology (Oxford) 2004 Jan; 43 (1): 73-894
96. Mumcu G, Yazici Y, Chamberlain A. Disease assessment in Behcet's disease. In: Yazici Y, Yazici Y, editors. Behcet's syndrome. New York: Springer, 2010: 299-315
97. Cekmen M, Evereklioglu C, Er H, et al. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behcet's syndrome. Int J Dermatol 2003 Nov; 42 (11): 870-5
98. Nanke Y, Kotake S, Goto M, et al. Decreased percentages of regulatory T cells in peripheral blood of patients with Behcet's disease before ocular attack: a possible predictive marker of ocular attack. Mod Rheumatol 2008; 18 (4): 354-8
99. Pay S, Abbasov T, Erdem H, et al. Serum MMP-2 and MMP-9 in patients with Behcet's disease: do their higher levels correlate to vasculo-Behcet's disease associated with aneurysm formation? Clin Exp Rheumatol 2007 Jul-Aug; 25 (4 Suppl. 45): 70-5
100. Bicer A, Tursen U, Kaya TI, et al. Bone mineral density in patients with Behcet's disease. Rheumatol Int 2004 Nov; 24 (6): 355-8
101. Tekin NS, Ozdolap S, Sarikaya S, et al. Bone mineral density and bone turnover markers of patients with Behcet's disease. J Eur Acad Dermatol Venereol 2007 Jan; 21 (1): 25-9
102. Justiniano M, Dold S, Espinoza LR. Rapid onset of muscle weakness (rhabdomyolysis) associated with combined use of simvastatin and colchicine. J Clin Rheumatol 2007 Oct; 13 (5): 266-8
103. Ford LT, Berg JD. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment: a pharmacogenomic test whose time has come. J Clin Pathol 2010 Apr; 63 (4): 288-95
104. Akman-Demir G, Ayranci O, Kurtuncu M, et al. Cyclosporine for Behçet's uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol 2008 Jul-Aug; 26 (4 Suppl. 50): S84-90
105. Kotake S, Higashi K, Yoshikawa K, et al. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology 1999 Mar; 106 (3): 586-9
106. Kö tter I, Gü naydin I, Batra M, et al. CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications: results of a retrospective analysis of 117 cases. Clin Rheumatol 2006 Jul; 25 (4): 482-6
107. Perez-Alvarez R, Diaz-Lagarez C, Garcia-Hernandez F, et al., BIOGEAS Study Group. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 case. Medicine (Baltimore) 2011 Nov; 90 (6): 359-71
108. Hayden, Frederick. Antimicrobial agents: antiviral agents. In: Hardman JG, Limbird LE, Gillman AG, editors. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill, 2001: 1313-47
109. Hamuryudan V, Kotter I. Medical management of Behcet's syndrome. In: Yazici Y, Yazici H, editors. Behcet's syndrome. New York: Springer, 2010: 317-38
110. Hatemi G, Silman A, Bang D, et al. Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis 2009 Oct; 68 (10): 1528-34
111. Erkek E, Ayaslioglu E, Erkek AB, et al. Response to vaccination against hepatitis B in patients with Behcet's disease. J Gastroenterol Hepatol 2005 Oct; 20 (10): 1508-11
112. Saad CG, Borba EF, Aikawa NE, et al. Immunogenicity and safety of the 2009 non-Adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic disease. Ann Rheum Dis 2011 Jun; 70 (6): 1068-73
113. National Center for Immunization and Respiratory Diseases. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) [published erratum appears in MMWR Recomm Rep 2011 Jul 29; 60: 993]. MMWR Recomm Rep 2011 Jan 28; 60 (2): 1-64
114. Sarica-Kucukoglu R, Akdag-Kose A, Kayabali M, et al. Vascular involvement in Behcet's disease: a retrospective analysis of 2319 cases. Int J Dermatol 2006 Aug; 45 (8): 919-21
115. Kobayashi M, Ito M, Nagakawa A, et al. Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behcet disease. Histopathology 2000 Apr; 36 (4): 362-71
116. Probst K, Fijnheer R, Rothova A. Endothelial cell activation and hypercoagulability in ocular Behcet's disease. Am J Ophthalmol 2004 May; 137 (5): 850-7
117. Sari RA, Kiziltunc A, Taysi S, et al. Levels of soluble E-selectin in patients with active Behcet's disease. Clin Rheumatol 2005 Feb; 24 (1): 55-9
118. Espinoza G, Font J, Tassies D, et al. Vascular involvement in Behcet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002 Jan; 112 (1): 37-43
119. Leiba M, Seligsohn U, Sidi Y, et al. Thrombophilic factors are not the leading cause of thrombosis in Behcet's disease. Ann Rheum Dis 2004 Nov; 63 (11): 1445-9
120. Mader R, Ziv M, Adawi M, et al. Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behcet's disease. J Rheumatol 1999 Nov; 26 (11): 2404-8
121. Ahn JK, Lee YS, Jeon CH, et al. Treatment of venous thrombosis associated with Behcet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 2008 Feb; 27 (2): 201-5
122. Desbois AC, Wechsler B, Resche-Rigon M, et al. Immunosuppressants reduce venous thrombosis relapse in Behçet's disease. Arthritis Rheum 2012 Aug; 64 (8): 2753-60